Filter
553
Text search:
M.tuberculosis
Featured
62
101
Language
Document type
380
80
41
26
12
9
3
2
Countries / Regions
43
25
22
14
10
10
9
9
9
9
8
8
7
7
6
6
6
6
6
5
5
4
4
4
4
4
3
3
3
3
3
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
165
67
12
6
6
6
3
Toolboxes
376
30
19
16
13
12
9
5
3
3
2
2
2
2
2
1
Protocol clinic naţional
PCN- 123
Eur Respir J. 2014 April ; 43(4): 1132–1141. doi:10.1183/09031936.00203613.
14–22 April 2015
Anti-tuberculosis drug resistance among tuberculosis patients in Ukraine and risk factors for MDR-TB
Results of the first national survey, 2013–2014
Epidemiologisches Bulletin; 14. März 2016 Nr. 10/11 ;DOI 10.17886/EpiBull-2016-014
Accessed December 2017
10–21 March 2014
Public Health Action PHA 2017; 7(2): 110–115
In case of resistance to rifampicin, fluoroquinolones become the preferred category of second-line drugs. Unfortunately, quinolone-resistant strains of Mycobacterium leprae have also been reported in several countries, probably due to the extensive use of quinolones for treating several types of inf
...
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
Latent Tuberculosis Infection : Updated and consolidated guidelines for programmatic management
recommended
The consolidated guidelines are expected to provide the basis and rationale for the development of national guidelines for LTBI management, adapted to the national and local epidemiology of TB, the availability of resources, the health infrastructure and other national and local determinants. The gu
...
2nd edition.
T The Compendium has been developed as a clear and concise instrument to facilitate the understanding and planning of delivery of high-quality care for everybody affected by TB. It incorporates all recent policy guidance from WHO; follows the care pathway of persons with signs or sympt
...
